Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeyondSpring Inc.BYSI · Entity 7539 | Director | April 01, 2026 | April 03, 2026 |
| PROGENICS PHARMACEUTICALS INCPGNX · Entity 148291 | CFO | March 02, 2020 | March 04, 2020 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Chief Financial Officer | January 26, 2026 | January 27, 2026 |
| Rafael Holdings, Inc.RFL · Entity 6620 | CFO & President | December 21, 2022 | December 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeyondSpring Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2036-04-01 | Direct | 22,165 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 22,165 · Balance 22,165 F1: Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All of the stock options will vest on April 1, 2027, subject to the Reporting Person's continuous service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All of the stock options will vest on April 1, 2027, subject to the Reporting Person's continuous service with the Issuer through such date.
PROGENICS PHARMACEUTICALS INC
Report date March 02, 2020 · Filed March 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.77 · Expires 2030-03-02 | Direct | 82,214 |
Reported balance
After 2020-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-02 · Grant · Acquired 82,214 · Balance 82,214 F1: 3yr 33% On Vest beginning on 02-Mar-2020 |
Filing footnotes · ownership attribution and instrument terms
F1: 3yr 33% On Vest beginning on 02-Mar-2020
Protara Therapeutics, Inc.
Report date January 26, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,115 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Tax withholding · Disposed 3,261 · Balance 64,115 F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025.
Rafael Holdings, Inc.
Report date December 21, 2022 · Filed December 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 335,175 |
Reported balance
After 2022-12-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-12-21 · Tax withholding · Disposed 27,928 · Balance 335,175 F1: Represents shares withheld by the Issuer for tax purposes upon vesting of Restricted Stock. F2: Consists of 50,139 shares of stock held directly and 285,036 shares of Restricted Stock that vest as follows: 19,517 shares to vest quarterly, commencing March 21, 2023, through December 21, 2023; and 25,871 shares to vest quarterly, commencing March 21, 2024 through December 21, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer for tax purposes upon vesting of Restricted Stock.
F2: Consists of 50,139 shares of stock held directly and 285,036 shares of Restricted Stock that vest as follows: 19,517 shares to vest quarterly, commencing March 21, 2023, through December 21, 2023; and 25,871 shares to vest quarterly, commencing March 21, 2024 through December 21, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 21:43 UTC | BeyondSpring Inc. BYSI · Entity 7539 | GrantStock Options (right to buy) · Derivative | 22,165 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001193125-26-142402 · ownership.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,165 Underlying: Ordinary Shares · 22,165 shares Expires 2036-04-01 F1 · derivative.exercise_date: Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All of the stock options will vest on April 1, 2027, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 3,261 | $6.67 | $21,750.87 |
DisclosureSEC source: 0001213900-26-008221 · marketforms-71931.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,115 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 24, 2025. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:30 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 3,063 | $5.60 | $17,152.80 |
DisclosureSEC source: 0001213900-26-006709 · marketforms-71771.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,376 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2024. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:37 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001213900-26-006230 · marketforms-71896.xml · derivative · entry 2 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2036-01-15 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:37 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-006230 · marketforms-71896.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,439 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| April 21, 2025 Filed Apr 23, 2025 12:58 UTC | BeyondSpring Inc. BYSI · Entity 7539 | GrantStock Options (right to buy) · Derivative | 23,793 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000950170-25-056985 · ownership.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,793 Underlying: Ordinary Shares · 23,793 shares Expires 2035-04-21 F1 · derivative.exercise_date: Reflects the grant of stock options to purchase ordinary shares of the Issuer under the 2017 Omnibus Incentive Plan. All of the stock options will vest on April 21, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001213900-25-007530 · marketforms-67928.xml · derivative · entry 2 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-01-23 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 24, 2025 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 23,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-007530 · marketforms-67928.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,500 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 24, 2025. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 3,061 | $4.76 | $14,570.36 |
DisclosureSEC source: 0001213900-25-005966 · marketforms-67896.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,939 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 19, 2024. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 131,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001213900-24-005723 · marketforms-64339.xml · derivative · entry 2 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2034-01-18 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2024 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-005723 · marketforms-64339.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2024. Read SEC document |
| January 30, 2023 Filed Jan 30, 2023 21:52 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001213900-23-006044 · ownership.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-01-29 F1 · derivative.exercise_date: One-fourth of the shares shall vest on January 30, 2024 and the remainder of the shares will vest in a series of thirty-six successive equal monthly installments measured from January 30, 2024, subject to the Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan) with the Issuer through each such vesting date. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 15:04 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | Tax withholdingClass B Common Stock, par value $.01 per share | 27,928 | $1.76 | $49,153.28 |
DisclosureSEC source: 0001209191-22-062551 · doc4.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · CFO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,175 F1 · shares: Represents shares withheld by the Issuer for tax purposes upon vesting of Restricted Stock. F2 · balance_after: Consists of 50,139 shares of stock held directly and 285,036 shares of Restricted Stock that vest as follows: 19,517 shares to vest quarterly, commencing March 21, 2023, through December 21, 2023; and 25,871 shares to vest quarterly, commencing March 21, 2024 through December 21, 2025. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 13:50 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | GrantClass B Common Stock, par value $.01 per share | 363,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006650 · doc4.xml · nonDerivative · entry 1 Fabbio Patrick · CIK 0001658859 · CFO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,103 F1 · shares: Grant of Restricted Stock that vests as follows: 78,067 to vest on December 21, 2022; 19,517 shares to vest quarterly, commencing March 21, 2023, through December 21, 2023; and 25,871 shares to vest quarterly, commencing March 21, 2024 through December 21, 2025. F2 · balance_after: Consists of shares of Restricted Stock that vest as follows: 78,067 to vest on December 21, 2022; 19,517 shares to vest quarterly, commencing March 21, 2023, through December 21, 2023; and 25,871 shares to vest quarterly, commencing March 21, 2024 through December 21, 2025. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 18:51 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | GrantEmployee Stock Option (right to buy) · Derivative | 105,602 | $0.00 Strike: $36.32 | $0.00 |
DisclosureSEC source: 0001209191-21-056826 · doc4.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,602 Underlying: Class B Common Stock · 105,602 shares Expires 2031-09-16 F1 · derivative.exercise_date: Options vest as follows: 25% shall vest on September 17, 2022 and additional equity with respect to 2.0833% of the options shall vest on each monthly anniversary thereafter, such that all equity shall vest by September 17, 2025. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:15 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 82,214 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0001562180-20-002131 · primarydocument.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,214 Underlying: Common Stock · 82,214 shares Expires 2030-03-02 F1 · derivative.exercise_date: 3yr 33% On Vest beginning on 02-Mar-2020 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 15:53 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 90,750 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001562180-19-001668 · primarydocument.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,750 Underlying: Common Stock · 90,750 shares Expires 2029-03-01 F1 · derivative.exercise_date: 3yr 33% On Vest beginning on 01-Mar-2019 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 13:09 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 94,875 | $0.00 Strike: $6.62 | $0.00 |
DisclosureSEC source: 0001562180-18-001354 · primarydocument.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,875 Underlying: Common Stock · 94,875 shares Expires 2028-03-01 F1 · derivative.exercise_date: 3yr 33% On Vest beginning on 01-Mar-2018 Read SEC document |
| March 01, 2017 Filed Mar 7, 2017 11:35 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001562180-17-001135 · primarydocument.xml · derivative · entry 1 Fabbio Patrick · CIK 0001658859 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2027-03-01 F1 · derivative.exercise_date: 3yr 33% On Vest beginning on 01-Mar-2017 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.